Fig. 8: PGK1 reprograms glucose metabolism and contributes to ESCC progression.
From: Integrative proteogenomic characterization of early esophageal cancer
a Pan Serine/Threonine/Tyrosine-phosphorylation levels of PGK1 in KYSE150 cells, KYSE70 cells, ECA109 cells, and TE-8 cells. b PGK1 level in mitochondria and cytosol fraction of in KYSE150 cells, KYSE70 cells, ECA109 cells, and TE-8 cells. c The impacts of PGK1 and/or ERK2 on PDHK1 T338 phosphorylation levels in KYSE150 cells, KYSE70 cells, ECA109 cells, and TE-8 cells. d The impacts of PGK1 and/or ERK2 on PDH activity in KYSE150 cells (n = 36) and ECA109 cells (n = 36) (two-sided Student’s t-test, mean ± SD). KYSE150: p = 0.088, *p = 0.031, ****p = 7.7E–6, p = 0.81, p = 0.66 from left to right. ECA109: *p = 0.043, p = 0.052, ****p = 1.3E–7, p = 0.78, p = 0.058 from left to right. e The impacts of overexpressed and knockdown PGK1 and ERK2 on OCR and ATP production (two-sided Student’s t-test, mean ± SD). Twenty-four cell samples were used in the analysis. Top: ****p = 1.6E–8 (PGK1), ****p = 2.6E–12 (PGK1 + ERK2). Bottom: ***p = 7.7E–4. OCR: oxygen consumption rate. f The impacts of overexpressed and knockdown PGK1 and ERK2 on ECAR (two-sided Student’s t-test, mean ± SD). Sixteen cell samples are used in the analysis. Top: **p = 1.2E–3 (PGK1), ****p = 1.0E–11 (PGK1 + ERK2). Bottom: ***p = 3.9E–7. ECAR: extracellular acidification rate. g The impacts of PGK1-overexpression (OE) and/or ERK2-OE on cell proliferation in KYSE150 cells, KYSE70 cells, ECA109 cells, and TE-8 cell (two-sided Student’s t-test, mean ± SD). A total of 320 cell samples were used in the analysis. KYSE150: ****p = 1.5E–7 (PGK1), ****p = 1.6E–5 (ERK2), ****p = 2.9E–9 (PGK1 + ERK2). KYSE70: *p = 0.014 (PGK1), **p = 4.5E–3 (ERK2), ****p = 6.8E–5 (PGK1 + ERK2). ECA109: ****p = 5.4E–7 (PGK1), ****p = 3.2E–6 (ERK2), ****p = 2.7E–9 (PGK1 + ERK2). TE-8: **p = 2.1E–3 (PGK1), ***p = 5.0E–4 (ERK2), ***p = 3.2E–4 (PGK1 + ERK2). h Gemcitabine inhibits cell proliferation (n = 30, two-sided Student’s t-test, **p = 4.8E–3, mean ± SD). i The impacts of PGK1-OE (left) and PGK1 knockdown (right) on the weight of the xenografts in the KYSE150 cells, ECA109 cells, and TE-8 cells (two-sided Student’s t-test, mean ± SD). A total of 130 samples are used in the analysis. Left: KYSE150: ****p = 5.9E–8 (Control and PGK1-OE), ****p = 4.4E–9 (PGK1-OE and PGK1-OE-inhibitor), p = 0.17 (Control and PGK1-OE-inhibitor). ECA109: ****p = 2.1E–8 (Control and PGK1-OE), ****p = 4.4E–9 (PGK1-OE and PGK1-OE-inhibitor), p = 0.17 (Control and PGK1-OE-inhibitor). TE-8: ****p = 1.3E–7 (Control and PGK1-OE), ****p = 4.0E–8 (PGK1-OE and PGK1-OE-inhibitor), p = 1.7E–3 (Control and PGK1-OE-inhibitor). Right: ****p = 8.6E–8 (KYSE150), ****p = 3.4E–7 (ECA109), ****p = 7.6E–8 (TE-8). ****p < 1.0E–4, ***p < 1.0E–3, **p < 0.01, *p < 0.05, ns. > 0.05. Source data are provided as a Source data file.
